Colchicine in Detail
On this page
Direct answer
An alkaloid of autumn crocus, prescribed since Byzantine physicians, colchicine now carries first-line labels in gout, pericarditis and familial Mediterranean fever. It binds tubulin and halts microtubule assembly, arresting neutrophil chemotaxis and inhibiting NLRP3-inflammasome signalling — anti-inflammatory, never analgesic. The modern gout regimen is low dose: 1 mg followed by 0.5 mg an hour later on day one (US labelling: 1.2 mg then 0.6 mg), then 0.5 mg once or twice daily as needed — the AGREE trial showed this matches high dose with far less diarrhoea. Toxicity is dose-related: diarrhoea first, then marrow suppression and myopathy; the fatal trap is combining standard doses with P-glycoprotein and CYP3A4 inhibitors — clarithromycin has killed patients.
What you must remember
- Mechanism: tubulin polymerisation blockade → neutrophil migration arrested; NLRP3 inflammasome inhibition reduces IL-1β — the modern framing examiners increasingly want.
- Acute gout (EULAR-style): 1 mg then 0.5 mg after 1 hour on day 1, continuing 0.5 mg once or twice daily during the attack; best started within 24 hours of onset.
- Pericarditis: 0.5 mg once or twice daily (1 mg twice daily if over 70 kg) added to aspirin/NSAIDs — three months for a first episode, six months for recurrence; ESC class I with trial backing (COPE, ICAP).
- Familial Mediterranean fever: 1–2 mg daily lifelong; also used in Behçet disease and as an anti-inflammatory adjunct elsewhere.
- Toxicity ladder: diarrhoea (dose-limiting, early), then vomiting; marrow suppression; myopathy and neuropathy — worsened by renal impairment and statins; no specific antidote.
- Fatal interaction: P-gp inhibitors plus strong CYP3A4 inhibitors — clarithromycin, cyclosporine, some azoles; avoid or halve the dose; also avoid repeat courses closer than three days apart in renal impairment.
- Renal dosing: eGFR 30–50 → reduced doses; eGFR below 10 → avoid; the narrow therapeutic index makes "colchicine is safe in CKD" a dangerous half-truth.
- NLEM anchor: colchicine 0.5 mg appears on India's NLEM 2022 — access is generic and cheap.
A CKD-3 gout attack with a statin on board
A 66-year-old man, eGFR 42, on atorvastatin and low-dose aspirin, presents with a first metatarsophalangeal attack starting 20 hours ago. The arithmetic: full-dose NSAID is risky for his kidneys; low-dose colchicine is reasonable — 1 mg at once, 0.5 mg an hour later, then 0.5 mg daily or twice daily for up to three days, total exposure deliberately capped for his eGFR. The interaction screen runs before the first tablet: no clarithromycin for any chest infection this season (the fatal pair), statin held if diarrhoea or muscle pain appears, paracetamol as the safe analgesic partner. He asks why the old prescription from years ago — 1 mg three times daily — is gone: the AGREE trial answered that, equal efficacy at a third of the GI toxicity. This case compresses the entire examinable surface — low-dose regimen, renal cap, interaction screen, statin vigilance — and each element is a separate mark.
Where students slip
The first slip is calling colchicine an analgesic — it does nothing for ordinary pain and everything for neutrophil-driven inflammation; the sentence matters in gout versus simple backache. The second is the legacy high-dose regimen (1 mg three times daily) persisting in older prescriptions; quoting AGREE and the 1 + 0.5 schedule marks the answer as current. Third, the interaction: students list "CYP3A4" generically and miss that clarithromycin plus colchicine at standard doses has caused fatal multi-organ failure — the pairing to name aloud. Fourth, pericarditis is missed entirely: colchicine's non-gout indications (acute and recurrent pericarditis, FMF, Behçet) are the difference between a gout answer and a drug answer. Fifth, renal dosing swings both ways — colchicine is used in mild CKD with care, not banned; blanket avoidance is as wrong as full dosing. Finally, the inflammasome mechanism connects colchicine to the IL-1 biologics (anakinra) used in refractory gout — the link examiners use to test depth.
Frequently asked questions
Why has the colchicine dose for gout fallen?
The AGREE trial showed low dose (1 mg then 0.5 mg at 1 hour) matched high-dose efficacy with far less diarrhoea and toxicity.
What is colchicine's role in pericarditis?
First-line with aspirin or NSAIDs — 0.5 mg once or twice daily for three months (six for recurrence), reducing recurrence rates.
Which interaction makes colchicine lethal?
P-gp plus strong CYP3A4 inhibitors, classically clarithromycin — standard doses then reach toxic levels causing marrow failure and multi-organ death.
Why does colchicine help familial Mediterranean fever?
It inhibits the neutrophil-driven NLRP3 inflammasome pathway driving serositis; 1–2 mg daily lifelong reduces attacks and amyloidosis risk.
Is colchicine safe in chronic kidney disease?
With dose reduction in moderate CKD and avoidance below eGFR 10 — the narrow therapeutic index demands capping, not blanket use.